MedTech startup EzeRx raises undisclosed amount as seed funding from Mankind Pharma promoters
The fund raised will be used for scaling up its operations and marketing along with boosting its sales in various markets across India, Africa, and South East Asia, seeking global certifications and boosting its R&D efforts.
Advertisement
Delhi: Bhubaneswar-based MedTech Startup, EzeRx Health Tech Private Limited, has received seed funding from certain promoters of Mankind Pharma Limited, including Mr. Sheetal Arora, the CEO of Mankind Pharma Limited.
EzeRx, founded in 2018 by Partha, along with its Co-Founders Chaitali Roy and Sudip Roy Chowdhury is an easy, painless and non-invasive screening solution to identify primary health parameters at an early stage such as, ailments in liver, kidney, lungs and blood glucose level and common problems like Anaemia, in less than a minute without withdrawing blood from the human body.
"The collaboration is aimed at strengthening the healthcare infrastructure while integrating more advanced screening solutions accessible across the country, taking a more patient-centric approach," the company stated.
The fund raised will be used for scaling up its operations and marketing along with boosting its sales in various markets across India, Africa, and South East Asia, seeking global certifications and boosting its R&D efforts.
On the occasion, Partha, Founder of EzeRx said, "Proper detection of health problems is the very first step in curing the ailment. Therefore, we intensively worked toward developing and manufacturing advanced medical devices for the effective management of the curative and preventive healthcare ecosystem. We are glad and thankful to Sheetal Arora for bestowing trust in us. He has always believed in serving society, and his vision to have all relevant technology and services in the medical field is admirable. This funding will help our company in securing partnerships with healthcare providers to integrate our products into their platform and partnering with hospitals and small clinics for the deployment of our products."
Looking forward to the collaboration, Sheetal Arora, a Promoter and the CEO of Mankind Pharma Limited said, "Preventive Care is the future of healthcare. Today, high costs of tests, short supply of machines, and other inconveniences make people ignore their health concerns. The need of the hour is to shape the future of healthcare services into a more patient centric domain. To add to that, in order to strengthen the healthcare infrastructure of the country, it is important that we take these services and extend them beyond the metropolitan cities and provide them at affordable prices to allow for more inclusivity across all economic stratas. EzeRx, I believe, is an example of one such device. EzeRx primarily focuses on providing high accuracy screening solutions, using a hand-held device, for everyday primary health-related concerns that many a time go unnoticed because of their passivity. These tests take less than a minute and don't involve any withdrawing of blood from the human body, making it a pain free and convenient experience. It is my strong belief that devices like EzeRx will change people's approach towards healthcare in India."
Earlier, EzeRx raised grants from NIDHI Prayas by DST, BIG program by DBT- BIRAC, SASACT Grant from MeiTy, Startup Grant from Indian Oil Corporation and Startup Odisha.
EzeRx has received the Aarohan Gold award from Infosys Foundation in 2019, 1st runner up in TATA Social Enterprise Challenge, most promising Brands from Odisha, and recently, won India Sweden Health care Challenge.
Read also: MOPE invests Rs 194 crore in Mankind Pharma diagnostics venture Pathkind
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.